Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
POLY MEDICURE LIMITED reports Fourth Quarter and Annual Results for FY 2015-16 - The Pharma Times | Pharma & Health Care News Portal

POLY MEDICURE LIMITED reports Fourth Quarter and Annual Results for FY 2015-16

New Delhi, May 19, 2016: POLY MEDICURE LIMITED, the leading manufacturers of medical devices and disposables under the brand name Polymed, announced its fourth quarterly results for quarter ending March 31, 2016 and Annual results besides providing other general business updates. The company reported net turnover of Rs.394.47 crore. “Polymed is now entering an exciting new chapter in line with the Government’s ‘Make in India’ theme which can be played in three parts through import substitution, enhanced domestic consumption and manufacturing exports. We are going to invest Rs.60 crores in a new green field project at IMT, Faridabad in Haryana and geared up to launch a slew of products in the coming year. , states Mr. Himanshu Baid, Managing Director. “The company has increased its EBIDTA which shows there is a significant margin improvement in the business.” adds Mr. Baid.

Results for the quarter and year ended March 31, 2016

Highlights of the Results

HIGHLIGHTS OF QUARTER’S PERFORMANCE

· Revenue (turnover) increased by 9.05% to 106.76 crores.

· EBITA margin Increased by 46.28% to 22.99 crores

· Profit Before Tax increased by 49.80 % to 20.94 crores

· Net Profit increased by 19.02% to 14.40 crores

HIGHLIGHTS OF YEAR’S PERFORMANCE

· Revenue (turnover) increased by 5.56% to 394.47 crores.

· EBITA margin increase by 0.15% to 72.65 crores.

· Profit Before Tax increased by 0.52% (without considering exceptional income of Rs. 19.57 crores during last year) to 64.87 crores.

· Net Profit decreased by 22.46 % to 47.30 crores due to exceptional income in last year

CORPORATE HIGHLIGHTS

· The Company will invest approx. 60 Crore in a new Green field project.

· The Company will focuses more on domestic market.

· The Board of Directors have recommended final dividend of Rs. 0.50/- share of Rs. 5 each in addition to interim dividend of Rs. 2.50/- share of Rs. 5/- each declared and paid in the month of March.

Corporate Comm India (CCI Newswire)

The Pharma Times News Bureau

Recent Posts

Fortis Hospital, Bannerghatta Road Launches dedicated Parkinson’s Disease and Deep Brain Stimulation Clinic

-  This specialized division empowers patients with neurological disorders to reclaim their mobility through a…

3 days ago

Milestone set in Indian Medical History – SSI Mantra Surgical Robotic System Performs the First-Ever Successful Surgery on One-Year-Old Infant

SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…

5 days ago

Manipal Hospital Ghaziabad organises Fire Safety Training to Enhance Emergency Response

Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…

2 weeks ago

Professor Dr Robert Zeiser receives DKMS Mechtild Harf Science Award 2024

DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…

3 weeks ago

Dr. Reddy’s launches drug-free migraine management device Nerivio® in Europe following successful launch in India

Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…

3 weeks ago

Ankura Hospital Doctors perform a successful Complex Lung Surgery on a 4-month-old Infant

 Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…

3 weeks ago